Clinical trial aims to address vaginal complaints after breast cancer diagnosis

FDA adds stereotactic breast biopsy needles to the shortage list

FDA has added stereotactic breast biopsy needles to its Medical Device Shortages List with an estimated duration of “through Q4 2026,” which spans July 1 to Sept. 30.

FDA issues reminder to sponsors: Disclose clinical trial results

FDA issued a stern reminder to medical product companies and researchers of the requirements to submit certain clinical trial results information to ClinicalTrials.gov.

Salwan Al Mutar named director of clinical research at START Dallas-Fort Worth

The START Center for Cancer Research, a community-based network of clinical trial sites specializing in early-phase oncology trials, announced the appointment of Salwan Al Mutar as director of Clinical Research at START Dallas-Fort Worth.

April 17, 2026

Vol.52 No.15

In Brief

Sheila Efron Taube honored by Brandeis with Alumni Achievement Award

Brandeis University has announced that Sheila Efron Taube ’63, a pioneer in cancer research, will receive the Alumni Achievement Award for outstanding contributions to their fields and society.

April 17, 2026

Vol.52 No.15

Clinical Roundup

ATOMIC phase III trial establishes standard-of-care for patients with stage 3 dMMR colon cancer

Patients with stage 3 colon cancer with deficient DNA mismatch repair had significantly better outcomes when the immunotherapy drug atezolizumab (Tecentriq) was added to standard chemotherapy after surgery, according to a study by researchers at the Alliance for Clinical Trials in Oncology.

April 17, 2026

Vol.52 No.15

Clinical Roundup

Experimental drug doubles one-year survival in pancreatic cancer trial, Northwestern study finds

Patients with pancreatic cancer who received the experimental drug elraglusib, alongside standard chemotherapy, were twice as likely to be alive after one year of treatment, compared to those receiving chemotherapy alone, according to the results of a randomized phase II clinical trial conducted by researchers at Northwestern University. The drug also reduced the risk of death by 38%.

April 17, 2026

Vol.52 No.15

Clinical trial aims to address vaginal complaints after breast cancer diagnosis

YOU MAY BE INTERESTED IN

FDA adds stereotactic breast biopsy needles to the shortage list

FDA issues reminder to sponsors: Disclose clinical trial results

Salwan Al Mutar named director of clinical research at START Dallas-Fort Worth

Sheila Efron Taube honored by Brandeis with Alumni Achievement Award

ATOMIC phase III trial establishes standard-of-care for patients with stage 3 dMMR colon cancer

Experimental drug doubles one-year survival in pancreatic cancer trial, Northwestern study finds

Renew today!

Subscriber content

Never miss an issue!

Login